Purpose To assess the incidence of acute postoperative endophthalmitis (POE) after cataract surgery combined with corneal, glaucoma or vitreoretinal surgical procedures from 2005 to 2014 in France.
Methods In this cohort study, acute POE occurring within 6 weeks after surgery was identified by means of billing codes recorded in a national database in patients operated for cataract extraction with phacoemulsification, or corneal, glaucoma or vitreoretinal surgical procedures, either combined or stand-alone.
Results From January 2005 to December 2014, up to 6 260 477 eyes underwent phacoemulsification cataract surgery as a single procedure and 115 468 eyes underwent phacoemulsification combined with corneal, glaucoma or vitreoretinal surgical procedures. The crude incidence of acute POE after stand-alone or combined cataract surgery was 0.102% and 0.149%, respectively. In multivariate Poisson analysis, combined surgery taken as a whole was at higher risk than cataract stand-alone surgery, with an adjusted incidence rate ratio (IRR) (95% CI) of 1.38 (1.11 to 1.70; p=0.0054). Glaucoma surgeries were associated with a lower acute POE incidence compared with phacoemulsification, conversely to vitreoretinal surgical procedures: IRR 0.63 (0.47 to 0.85; p<0.001) and IRR 1.78 (1.58 to 2.01; p<0.001), respectively.
Conclusion A higher incidence of acute POE after combined cataract surgery than after cataract surgery done as a stand-alone procedure was observed based on the French nationwide medical-administrative database. The incidence of acute POE after combined surgery was related to the type of surgery performed simultaneously with cataract extraction.
Statistics from Altmetric.com
Contributors Conception and design: CPCG, VD, JFK, AMB, CQ. Data acquisition: ASM, EB. Statistical analysis and interpretation: CPCG, ASM, EB, AMB, CQ. Drafting the article: CPCG, VD, JFK, AMB. Final approval of the version to be published: CPCG, ASM, EB, VD, JFK, AMB, CQ.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests EB, ASM and CQ have nothing to disclose. VD reports personal fees and non-financial support from Bayer, Novartis, Alcon, Horus and Thea outside the submitted work. JFK reports personal fees from Alcon, Allergan, Alimera, Bayer, Novartis, Roche, Thea and Zeiss outside the submitted work. AMB reports personal fees from Allergan and Bausch Lomb, grants from Horus, personal fees from Thea and Zeiss outside the submitted work. CPCG reports grants and personal fees from Allergan, Bayer, Novartis, Horus and Thea outside the submitted work.
Patient consent Not required.
Ethics approval Use of this database was approved by the National Commission for Data Protection (CNIL No. 1576793) and this study adhered to the tenets of the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.